SMARCA4 (SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily A, member 4)

Despite presenting with locally advanced pT4a disease and early pulmonary metastasis, the patient achieved 5-year local control following total laryngectomy and adjuvant radiotherapy. The findings suggest that molecular profiling can identify non-MYB-driven subtypes and guide individualized management for atypical laryngeal malignancies.

The regimen included ifosfamide, liposomal doxorubicin hydrochloride, cadonilimab, and anlotinib capsules...Here we present a successfully treated case of this tumor type originating in the stomach. This case may serve as a reference for future management of such tumors.

SMARCA4 deficiency defined an aggressive subset of lung cancer characterised by distinct clinicopathological features and was associated with significantly shorter median OS than SMARCA4-proficient tumours. ICI-based therapy may significantly improve survival outcomes in SMARCA4-deficient patients, supporting its prioritisation in this high-risk population.

The genetic test map suggested high PD-L1 expression (TPS 80%) and the patient was treated with sindilizumab (200 mg q3w) combined with bevacizumab (500 mg q3w). During follow-up, the patient achieved a final OS of 18 months. This case suggests that PD-1 inhibitors combined with antiangiogenic therapy may improve the prognosis of SMARCA4-UT, but the adverse effects observed during the treatment course demanded equally critical attention.

This study revealed the distinct clinicogenomic landscapes of NRG1 fusions and SNVs in NSCLC. These findings emphasize the important role of molecular profiling for precision diagnosis and individualized treatment of NSCLC.

Furthermore, single-agent treatment of S63845 resulted in significant suppression of tumor growth in patient-derived xenografts of SMARCA4/2-deficient NSCLC and SCCOHT. Collectively, our work uncovered MCL1 as a synthetic lethal target in SMARCA4/2-deficient cancers that may be exploited therapeutically.

These tumors are highly aggressive and often present at advanced stages. In the sinonasal region, they can mimic olfactory neuroblastoma, while in other H&N sites, they can resemble neuroendocrine carcinoma.

Moreover, genome-wide association studies (GWAS) suggested that genetic variants in SERPINE2 and related genes may increase bladder cancer susceptibility. Collectively, our findings provide novel insights into neuro-immune-driven tumor heterogeneity and immune remodeling, establish the NAS model as an innovative prognostic tool, and identify SERPINE2 as a promising therapeutic target for precision management of bladder cancer.

After six cycles of tislelizumab + paclitaxel/cisplatin, the lesion demonstrated partial remission and progressive cavitation on CT imaging. This case highlights that PD-L1 expression and radiologic cavitation may serve as potential efficacy biomarkers in SMARCA4-UTs, even in tumors with TP53 mutations and a high proliferative index. Combined immunotherapy with chemotherapy and radiotherapy may confer durable disease control in this aggressive lung cancer subtype.

The methylation status of the MLH1 promoter has limited value in predicting the prognosis of dMMR EEC. Molecular pathways heterogeneity between the methylated and nonmethylated subgroups suggests the necessity of integrate multi-dimensional indicators to optimize stratification strategies, instead of relying on a single epigenetic marker.